Clinical Trial Update: Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Non Hodgkin's Lymphoma (NHL) Patients With Greater Than 25% Bone Marrow Involvement [Phase 1]

View source ↗

Summary

Phase 1 trial assessing the safety and efficacy of an iodine-131 labeled anti-B1 antibody in non-Hodgkin lymphoma patients with >25% bone marrow involvement. Th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Iodine-131 anti-B1 antibody (iodine-131 labeled anti-B1 antibody)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Lymphoma, Non-Hodgkin | Phase 1 | Status: COMPLETED